The area of lymphokines and cytokines is expanding at an enormous rate. Already the clinical value of the rDNA interferons is becoming more clearly defined. Interleukin-2 holds considerable therapeutic promise, but toxicity is a serious problem with this agent. Considerably more clinical development will be required before a reasonable evaluation of this agent is possible. The other newer agents discussed above are of great interest to clinicians and we look forward to a time when new and hopefully useful treatment options will become available for patients with cancer as a consequence of their clinical development.
CITATION STYLE
Wagstaff, J., & Melief, K. J. (1987). Lymphokines and cytokines. Cancer Chemotherapy and Biological Response Modifiers. https://doi.org/10.1007/978-94-009-0029-5_10
Mendeley helps you to discover research relevant for your work.